Natural Product (NP) Details

General Information of the NP (ID: NP0624)
Name
Meloxicam
Synonyms
meloxicam; 71125-38-7; Mobic; Metacam; Movalis; Mobicox; Meloxicam (Mobic); Mobec; Movatec; Parocin; Meloxicamum [Latin]; UH-AC 62XX; 4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; Meloxicamum; UNII-VG2QF83CGL; UHAC-62XX; C14H13N3O4S2; 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; VG2QF83CGL; CHEMBL599; MLS000028587; CHEBI:6741; MFCD00868752; NCGC00018248-04; SMR000058994; DSSTox_CID_803; Meloxicam, 99-101%; N-1539; DSSTox_RID_75796; DSSTox_GSID_20803; Revmoksikam; Coxflam; Coxicam; Melonex; Meloxivet; Tenaron; Vivlodex; Melfax; (E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2H-benzo[e][1,2]thiazin-4(3H)-one 1,1-dioxide; CAS-71125-38-7; CCRIS 9139; Ilacox; HSDB 7741; Meloxicam [USAN:USP:INN:BAN]; Meloxicam,(S); 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1?^{6},2-benzothiazine-3-carboxamide; Mobic (TN); Opera_ID_2; Spectrum_001633; Spectrum2_000941; Spectrum3_000649; Spectrum4_000787; Spectrum5_001813; SCHEMBL3576; Meloxicam (JAN/USP/INN); Lopac0_000766; SCHEMBL33369; BSPBio_002257; KBioGR_001234; KBioSS_002113; MLS001304725; MLS001306413; MLS006011422; BIDD:GT0726; SCHEMBL713100; SPECTRUM1504150; UH-AC-62 XX; SPBio_000902; GTPL7220; CHEMBL1741042; DTXSID1020803; KBio2_002113; KBio2_004681; KBio2_007249; KBio3_001477; ETI-511; HMS1922D19; HMS2089B18; HMS2096I19; HMS2234P07; HMS2236C09; HMS3259H06; HMS3372C13; HMS3372P18; HMS3655K06; HMS3713I19; HMS3744K09; HMS3884G08; ALBB-027268; AMY40407; BCP11928; HY-B0261; Tox21_111734; Tox21_113192; Tox21_201689; Tox21_302756; ANW-57553; BBL029076; BDBM50056998; CCG-39098; HSCI1_000045; s1734; STK620505; ZINC13129998; Meloxicam - CAS 71125-38-7; AKOS000279442; AKOS026749959; Tox21_111734_1; ZINC103620661; AC-1325; DB00814; KS-1084; MCULE-4138373089; NC00698; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide; 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; SMP2_000133; Meloxicam 100 microg/mL in Acetonitrile; NCGC00018248-01; NCGC00018248-02; NCGC00018248-03; NCGC00018248-05; NCGC00018248-06; NCGC00018248-07; NCGC00018248-08; NCGC00018248-10; NCGC00018248-23; NCGC00018248-26; NCGC00022924-03; NCGC00022924-04; NCGC00256316-01; NCGC00259238-01; NCGC00263878-02; (E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2,3-dihydro-4H-benzo[e][1,2]thiazin-4-one 1,1-dioxide; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide; AK-77454; SMR000718800; AB0007297; DB-055490; Meloxicam 1.0 mg/ml in Dimethyl Sulfoxide; FT-0628193; M1959; R3928; SW219562-1; EN300-52507; C08169; D00969; J10218; AB00383033-17; AB00383033-18; AB00383033_20; 125M387; A837087; AN-668/13244001; Q414028; SR-01000003132-10; F2173-0387; Z1695493323; O=C1C2=CC=CC=C2S(=O)(=O)N(C)\\C1=C(\\O)NC1=NC=C(C)S1; 4-hydroxy-2-methyl-N-(5-methy-2-thiazolyl)-2H-1,2-benzothiazine-3-caboxamide-1,1-dioxide; (3Z)-2-methyl-3-[[(5-methyl-1,3-thiazol-2-yl)amino]-oxidanyl-methylidene]-1,1-bis(oxidanylidene)-1$l^{6},2-benzothiazin-4-one; (3Z)-3-[hydroxy-[(5-methyl-2-thiazolyl)amino]methylidene]-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazin-4-one; 133687-22-6; 4-Hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide; 4-Hydroxy-2-methyl-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1$l^{6},2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1lambda6,2-benzothiazine-3-carboxamide; 4-hydroxy-2-methyl-N-(5-methyl-2-thiazole)-2H-1,2-benzothiazine-3 -carboxamide 1,1-dioxide
    Click to Show/Hide
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Rheumatoid arthritis [ICD-11: FA20] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C14H13N3O4S2
PubChem CID
54677470
Canonical SMILES
CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
InChI
1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
InChIKey
ZRVUJXDFFKFLMG-UHFFFAOYSA-N
CAS Number
CAS 71125-38-7
ChEBI ID
CHEBI:6741
TTD Drug ID
D0G7FJ
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Lidocaine      Corneal disease     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical observation
                    Experimental
                    Result(s)		 The results from this early experience are promising for a potentially effective topical treatment for vulvodynia.
Target and Pathway
Target(s) Prostaglandin G/H synthase 2 (COX-2)  Molecule Info  [3]
BioCyc Aspirin-triggered lipoxin biosynthesis Click to Show/Hide
2 Aspirin triggered resolvin D biosynthesis
3 C20 prostanoid biosynthesis
4 Aspirin triggered resolvin E biosynthesis
KEGG Pathway Arachidonic acid metabolism Click to Show/Hide
2 Metabolic pathways
3 NF-kappa B signaling pathway
4 VEGF signaling pathway
5 TNF signaling pathway
6 Retrograde endocannabinoid signaling
7 Serotonergic synapse
8 Ovarian steroidogenesis
9 Oxytocin signaling pathway
10 Regulation of lipolysis in adipocytes
11 Leishmaniasis
12 Pathways in cancer
13 Chemical carcinogenesis
14 MicroRNAs in cancer
15 Small cell lung cancer
NetPath Pathway IL1 Signaling Pathway Click to Show/Hide
2 TSH Signaling Pathway
3 IL4 Signaling Pathway
4 TGF_beta_Receptor Signaling Pathway
5 IL5 Signaling Pathway
Panther Pathway Endothelin signaling pathway Click to Show/Hide
2 Inflammation mediated by chemokine and cytokine signaling pathway
3 Toll receptor signaling pathway
4 CCKR signaling map ST
Pathwhiz Pathway Arachidonic Acid Metabolism Click to Show/Hide
Pathway Interaction Database Calcineurin-regulated NFAT-dependent transcription in lymphocytes Click to Show/Hide
2 S1P1 pathway
3 C-MYB transcription factor network
4 Signaling mediated by p38-alpha and p38-beta
5 Calcium signaling in the CD4+ TCR pathway
WikiPathways Prostaglandin Synthesis and Regulation Click to Show/Hide
2 Arachidonic acid metabolism
3 Aryl Hydrocarbon Receptor
4 Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
5 Spinal Cord Injury
6 Integrated Pancreatic Cancer Pathway
7 Eicosanoid Synthesis
8 Selenium Micronutrient Network
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7220).
Reference 2 Early experience with topical meloxicam and lidocaine combination for the treatment of vulvodynia. Can Urol Assoc J. 2018 Aug;12(8):252-255.
Reference 3 Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):21-7.
 Download Picture         KEGG Link